# A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease

> **NCT05036473** · PHASE2 · UNKNOWN · sponsor: **Shanghai WD Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05036473
- **Lead sponsor:** Shanghai WD Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-12
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-09-16
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036473, "A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05036473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*